Phase I dose-escalation study of AZD7762 a checkpoint kinase inhibitor in combination with gemcitabine in US patients with advanced solid tumors

摘要

PurposeAZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients.